FDA Oncology Announcements

MTOR inhibitor × Clear all

11 Announcements

FDA approves sirolimus protein-bound particles for malignant perivascular epithelioid cell tumor

Trial: AMPECT
Drug: sirolimus protein-bound particles · MTOR inhibitor
Condition: Sarcoma

FDA approves everolimus for tuberous sclerosis complex-associated partial-onset seizures

Trial: EXIST-3
Drugs: Afinitor Disperz (everolimus tablets for oral suspension) · MTOR inhibitor, Afinitor Disperz (oral suspension)
Condition: CNS

Lenvatinib in combination with Everolimus

Drugs: Lenvima (lenvatinib) · Multikinase inhibitor, everolimus · MTOR inhibitor
Conditions: EndocrineGenitourinary

Everolimus (Afinitor)

Drug: Afinitor (everolimus) · MTOR inhibitor
Condition: NET

Everolimus for Tuberous Sclerosis Complex (TSC)

Drug: Afinitor Disperz (everolimus tablets for oral suspension) · MTOR inhibitor
Condition: CNS

Everolimus 2012

Drugs: Afinitor (everolimus) · MTOR inhibitor, exemestane · Aromatase inhibitor third generation
Condition: Breast

Everolimus (2012)

Drug: Afinitor tablets (everolimus) · MTOR inhibitor
Condition: Breast

Everolimus 2011

Drug: Afinitor Tablets (everolimus) · MTOR inhibitor
Conditions: EndocrineGastrointestinalNET

Everolimus (Accelerated Approval)

Drug: Afinitor (everolimus) · MTOR inhibitor
Condition: CNS

Everolimus

Drug: AFINITOR (everolimus) · MTOR inhibitor
Condition: Genitourinary

Temsirolimus

Drug: Torisel (temsirolimus) · MTOR inhibitor
Condition: Genitourinary